Recent Research Analysts’ Ratings Changes for OrthoPediatrics (KIDS)

A number of research firms have changed their ratings and price targets for OrthoPediatrics (NASDAQ: KIDS):

• 1/27/2026 – OrthoPediatrics was upgraded by analysts at TD Cowen to a “strong-buy” rating.
• 1/26/2026 – OrthoPediatrics is now covered by analysts at TD Cowen. They set a “buy” rating and a $23.00 price target on the stock.
• 1/22/2026 – OrthoPediatrics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 1/17/2026 – OrthoPediatrics was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 12/20/2025 – OrthoPediatrics was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 12/10/2025 – OrthoPediatrics is now covered by analysts at Canaccord Genuity Group Inc.. They set a “buy” rating and a $24.00 price target on the stock.
• 12/10/2025 – OrthoPediatrics is now covered by analysts at Canaccord Genuity Group Inc.. They set a “buy” rating and a $24.00 price target on the stock.
• 12/6/2025 – OrthoPediatrics was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.